Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Solute carrier family 26 member 3 (SLC26A3, Protein DRA) is a membrane-bound glycoprotein essential for the absorption and exchange of chloride and bicarbonate ions at the apical membrane of the intestinal epithelium. It plays a central role in maintaining electrolyte and fluid balance in the colon, facilitates oxalate transport, and interacts functionally with the CFTR protein. Loss-of-function mutations cause congenital chloride diarrhea, while SLC26A3 inhibition is being investigated as a strategy for treating constipation, kidney stones, and other gut disorders. SLC26A3 is considered a potential therapeutic target and biomarker, with several small molecules developed to selectively inhibit its activity from either the extracellular or cytoplasmic surface, offering new routes for the modulation of gut epithelial ion transport.
Direct inhibition of SLC26A3-mediated chloride and oxalate absorption (extracellular and cytoplasmic inhibition by small molecules)
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Solute carrier family 26 member 3 (SLC26A3).